Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Ruxolitinib
Related studies linked through entity extraction aliases.
Ruxolitinib in Previously Treated Idiopathic Multicentric Castleman Disease
- Status
- RECRUITING
- Phase
- PHASE2
Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations
- Status
- RECRUITING
- Phase
- PHASE2
Biomarker-Guided Ruxolitinib for the Prevention of Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation
- Status
- RECRUITING
- Phase
- PHASE1
Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma
- Status
- RECRUITING
- Phase
- PHASE2
A Randomized Study to Compare Post-transplant Cyclophosphamide, Sirolimus, Ruxolitinib and Post-transplant Cyclophosphamide, Sirolimus, Mycophenolate Mofetil to Prevent Graft Versus Host Disease
- Status
- RECRUITING
- Phase
- PHASE2
MAGIC Ruxolitinib for aGVHD
- Status
- RECRUITING
- Phase
- PHASE2
A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis
- Status
- RECRUITING
- Phase
- PHASE3
Study of Efficacy and Safety of Ruxolitinib in Chinese Participants With Corticosteroid-refractory Chronic Graft vs. Host Disease
- Status
- RECRUITING
- Phase
- PHASE4
A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Ruxolitinib Based GVHD Prophylaxis Regimen Before, During, and After Hematopoietic Cell Transplantation in Older Adult Patients With Acquired Aplastic Anemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Upfront Ruxolitinib for Chronic Graft-vs-host Disease
- Status
- TERMINATED
- Phase
- PHASE1
Ruxolitinib vs Prednisone as First-line Therapy for cGVHD Needing Systemic Therapy
- Status
- RECRUITING
- Phase
- PHASE2
A Phase 2 Study of INCB57643 (BET Inhibitor) in Combination With Ruxolitinib in JAK Inhibitor-naïve Patients With Myelofibrosis
- Status
- WITHDRAWN
- Phase
- PHASE2
Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Efficacy and Safety of JAK Inhibitors in Patients With AA: RWE Study
- Status
- RECRUITING
- Phase
- N/A
Ruxolitinib Treatment in Inclusion Body Myositis
- Status
- RECRUITING
- Phase
- PHASE2
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
- Status
- RECRUITING
- Phase
- PHASE3
BeFluBu vs FluBuRux Conditioning in Haploidentical HCT
- Status
- RECRUITING
- Phase
- PHASE2
Study of Efficacy and Safety of Ruxolitinib in Patients With Grade II to IV Steroid-refractory Acute Graft vs. Host Disease
- Status
- RECRUITING
- Phase
- PHASE4